Citation: Ruiquan Liu, Wenwen Duan, Wenzhong Yan, Jinfeng Zhang, Jianjun Cheng. Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A_2A adenosine receptors and histone deacetylases[J]. Chinese Chemical Letters, ;2024, 35(1): 108136. doi: 10.1016/j.cclet.2023.108136 shu

Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A_2A adenosine receptors and histone deacetylases

Ruiquan Liu ^a ,
Wenwen Duan ^a ,
Wenzhong Yan ^a ,
Jinfeng Zhang ^a ,
Jianjun Cheng ^{a, b, *,}

a.
iHuman Institute, ShanghaiTech University, Shanghai 201210, China
b.
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China

chengjj@shanghaitech.edu.cn

Received Date: 11 October 2022
Revised Date: 3 January 2023
Accepted Date: 4 January 2023
Available Online: 5 January 2023

Figures(5)

The A_2A adenosine receptor (A_2AAR) has attracted attention as an emerging immunotherapeutic target with several antagonists being evaluated in clinical trials. However, A_2AAR antagonists show limited efficacy as monotherapies. Herein, we communicate our design and synthesis of a novel series of A_2AAR/histone deacetylase (HDAC) bifunctional inhibitors, based on the core structure of the A_2AAR antagonist PBF-509. The new compounds were designed using a pharmacophore-merging strategy and features a tri-substituted pyrimidine core. The binding affinity for A_2AAR and inhibitory activity against HDACs of all the new compounds were tested. A number of compounds exhibited nanomolar or subnanomolar activity against both targets and some showed equally potent antiproliferative activity against MC38, CT26 and HCT116 colon cancer lines compared to HDAC inhibitors SAHA and MGCD-0103 in vitro. The binding poses of compound 5a in both A_2AAR and HDAC1 were predicted by molecular docking studies. Collectively, these results suggest these tri-substituted pyrimidine derivatives are promising leads for developing A_2AAR/HDAC dual-acting compounds as novel antitumor agents.
- Bifunctional,
- A_2AAR antagonism,
- HDAC inhibition,
- Cancer,
- Immunotherapy
1. [1]
  J. Blay, T.D. White, D.W. Hoskin, Cancer Res. 57 (1997) 2602–2605.
2. [2]
  D. Vijayan, A. Young, M. Teng, et al., Nat. Rev. Cancer 17 (2017) 709–724. doi: 10.1038/nrc.2017.86
3. [3]
  B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, et al., Pharmacol. Rev. 63 (2017) 1–34. doi: 10.4324/9781315177151-1
4. [4]
  A. Ohta, M. Sitkovsky, Nature 414 (2001) 916–919. doi: 10.1038/414916a
5. [5]
  A. Ohta, E. Gorelik, S.J. Prasad, et al., Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13132–13137. doi: 10.1073/pnas.0605251103
6. [6]
  J. Kjaergaard, S. Hatfield, G. Jones, et al., J. Immunol. 201 (2018) 782–791. doi: 10.4049/jimmunol.1700850
7. [7]
  J. Zhang, W. Yan, W. Duan, et al., Pharmaceuticals 13 (2020) 237. doi: 10.3390/ph13090237
8. [8]
  F. Yu, C. Zhu, Q. Xie, et al., J. Med. Chem. 63 (2020) 12196–12212. doi: 10.1021/acs.jmedchem.0c00237
9. [9]
  A. Anighoro, J. Bajorath, G. Rastelli, et al., J. Med. Chem. 57 (2014) 7874–7887. doi: 10.1021/jm5006463
10. [10]
  Y. Ren, Q. Sun, Z. Yuan, et al., Chin. Chem. Lett. 30 (2019) 1233–1236. doi: 10.1016/j.cclet.2019.03.029
11. [11]
  Q. Sun, Q. Dai, C. Zhang, et al., Chin. Chem. Lett. 32 (2021) 2479–2483. doi: 10.1016/j.cclet.2021.02.004
12. [12]
  X. Cai, H.X. Zhai, J. Wang, et al., J. Med. Chem. 53 (2010) 2000–2009. doi: 10.1021/jm901453q
13. [13]
  C.J. Lai, R. Bao, T. Xu, et al., Cancer Res. 70 (2010) 3647–3656.
14. [14]
  C. Ding, D. Li, Y.W. Wang, et al., Chin. Chem. Lett. 28 (2017) 1220–1227. doi: 10.1016/j.cclet.2017.01.003
15. [15]
  K. Sun, R. Atoyan, M.A. B. orek, et al., Mol. Cancer Ther. 16 (2016) 285–299.
16. [16]
  Y. Huang, S. Chen, S. Wu, et al., Acta Pharm. Sin. B 10 (2020) 1294–1308. doi: 10.1016/j.apsb.2019.11.011
17. [17]
  S. Wu, Y. Huang, T. Wang, et al., J. Med. Chem. 65 (2022) 4818–4831. doi: 10.1021/acs.jmedchem.1c02026
18. [18]
  Y. Huang, G. Dong, H. Li, et al., J. Med. Chem. 61 (2018) 6056–6074. doi: 10.1021/acs.jmedchem.8b00393
19. [19]
  X. Liang, J. Zang, X. Li, et al., J. Med. Chem. 62 (2019) 3898–3923. doi: 10.1021/acs.jmedchem.8b01597
20. [20]
  W. Yan, L. Ling, Y. Wu, et al., J. Med. Chem. 64 (2021) 16573–16597. doi: 10.1021/acs.jmedchem.1c01155
21. [21]
  J. Zhang, Z. Luo, W. Duan, et al., Eur. J. Med. Chem. 236 (2022) 114326. doi: 10.1016/j.ejmech.2022.114326
22. [22]
  A. Borodovsky, C.M. Barbon, Y. Wang, et al., J. ImmunoTher. Cancer 8 (2020) e000417. doi: 10.1136/jitc-2019-000417
23. [23]
  J.A. Camacho Gomez, J.C. Castro-Palomino Laria, Patent, WO2011121418 A1, 2011.
24. [24]
  D.H. Slee, Y. Chen, X. Zhang, et al., J. Med. Chem. 51 (2008) 1719–1729. doi: 10.1021/jm701185v
25. [25]
  D. Slee, M. Lanier, B.G. Vong, et al., Patent, WO2006110884 A2, 2006.
26. [26]
  D. Slee, X. Zhang, J.K. Rueter, et al., Patent, WO2007084914 A2, 2007.
27. [27]
  B. Bernet, P.M. Bishop, M. Caron, et al., Can. J. Chem. 63 (1985) 2818–2820. doi: 10.1139/v85-470
28. [28]
  M. Mediavilla-Varela, J. Castro, A. Chiappori, et al., Neoplasia 19 (2017) 530–536. doi: 10.1016/j.neo.2017.02.004
29. [29]
  P.A. B. eavis, N. Milenkovski, M.A. H. enderson, et al., Cancer Immunol. Res. 5 (2015) 506–517.
30. [30]
  R.D. L. eone, I.M. S. un, M.H. O. h, et al., Cancer Immunol. Immun. 67 (2018) 1271–1284. doi: 10.1007/s00262-018-2186-0
1. [1]
  Meng Sun , Jiazhen Yang , Leijiao Li , Yunhui Li , Wenliang Li , Jianxun Ding . Engineered bacteria potentiate cancer immunotherapy. Chinese Chemical Letters, 2025, 36(9): 111093-. doi: 10.1016/j.cclet.2025.111093
2. [2]
  Shuang Liang , Jianjun Yao , Dan Liu , Mengli Zhou , Yong Cui , Zhaohui Wang . Tumor-responsive covalent organic polymeric nanoparticles enhancing STING activation for cancer immunotherapy. Chinese Chemical Letters, 2025, 36(3): 109856-. doi: 10.1016/j.cclet.2024.109856
3. [3]
  Yuequan Wang , Congtian Wu , Chengcheng Feng , Qin Chen , Zhonggui He , Shenwu Zhang , Cong Luo , Jin Sun . Spatiotemporally-controlled supramolecular hybrid nanoassembly enabling ferroptosis-augmented photodynamic immunotherapy of cancer. Chinese Chemical Letters, 2025, 36(3): 109902-. doi: 10.1016/j.cclet.2024.109902
4. [4]
  Yanjun Cai , Yong Jiang , Yu Chen , Erzhuo Cheng , Yuan Gu , Yuwei Li , Qianqian Liu , Jian Zhang , Jifang Liu , Shisong Han , Bin Yang . Amplifying STING activation and immunogenic cell death by metal-polyphenol coordinated nanomedicines for enhanced cancer immunotherapy. Chinese Chemical Letters, 2025, 36(5): 110437-. doi: 10.1016/j.cclet.2024.110437
5. [5]
  Xin Li , Xuan Ding , Junkun Zhou , Hui Shi , Zhenxi Dai , Jiayi Liu , Yongcun Ma , Penghui Shao , Liming Yang , Xubiao Luo . Utilizing synergistic effects of bifunctional polymer hydrogel PAM-PAMPS for selective capture of Pb(Ⅱ) from wastewater. Chinese Chemical Letters, 2024, 35(7): 109158-. doi: 10.1016/j.cclet.2023.109158
6. [6]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
7. [7]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
8. [8]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
9. [9]
  Rongrong Zheng , Zuxiao Chen , Qiuyuan Li , Ni Yang , Wenjun Zhang , Chuyu Huang , Linping Zhao , Xin Chen , Hong Cheng , Shiying Li . Endoplasmic reticulum targeting photodynamic oxidizer to boost anti-tumor immunity by intensifying immunogenic cell death in conjunction with IDO1 inhibition. Chinese Chemical Letters, 2025, 36(12): 110865-. doi: 10.1016/j.cclet.2025.110865
10. [10]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
11. [11]
  Donghu Yu , Junneng Wang , Lei Hu , Youxian Wu , Tianqing Wang , Zhiyu Li , Zefen Wang , Qihang Ding , Yao Sun , Zhiqiang Li . Knowledge structures and research hotspots of immunotherapy for brain metastasis, glioma, meningioma, and pituitary adenoma: A bibliometric and visualization review. Chinese Chemical Letters, 2025, 36(12): 110995-. doi: 10.1016/j.cclet.2025.110995
12. [12]
  Hao Cai , Xiaoyan Wu , Lei Jiang , Feng Yu , Yuxiang Yang , Yan Li , Xian Zhang , Jian Liu , Zijian Li , Hong Bi . Lysosome-targeted carbon dots with a light-controlled nitric oxide releasing property for enhanced photodynamic therapy. Chinese Chemical Letters, 2024, 35(4): 108946-. doi: 10.1016/j.cclet.2023.108946
13. [13]
  Xinyue Lan , Junguang Liang , Churan Wen , Xiaolong Quan , Huimin Lin , Qinqin Xu , Peixian Chen , Guangyu Yao , Dan Zhou , Meng Yu . Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2024, 35(4): 108616-. doi: 10.1016/j.cclet.2023.108616
14. [14]
  Bohan Chen , Liming Gong , Jing Feng , Mingji Jin , Liqing Chen , Zhonggao Gao , Wei Huang . Research advances of nanoparticles for CAR-T therapy in solid tumors. Chinese Chemical Letters, 2024, 35(9): 109432-. doi: 10.1016/j.cclet.2023.109432
15. [15]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
16. [16]
  Weiqian Jin , Lin Liao , Tao Qin , Xiaoxuan Guan , Huyang Gao , Peng Liang , Ming Gao , Junyu Lu . Recent advances in nanomedicine therapy for bacterial pneumonia. Chinese Chemical Letters, 2025, 36(6): 110920-. doi: 10.1016/j.cclet.2025.110920
17. [17]
  Qi Wei , Hua Xin , Xiaolong Wang , Changjuan Qin , Yuanzhen Su , Di Li , Jianxun Ding . Unimolecular chiral poly(amino acid)s as adjuvants of nanovaccines for augmented cancer immunotherapy. Chinese Chemical Letters, 2025, 36(11): 111477-. doi: 10.1016/j.cclet.2025.111477
18. [18]
  Ying Sun , Minglong Chen , Ying Chen , Wanchen Zhao , Yanping Fu , Zhengwei Huang , Chao Lu , Chuanbin Wu , Xin Pan , Guilan Quan . Dissolving microneedle-assisted in situ cancer vaccine combined with cytolytic peptide for anti-melanoma immunotherapy. Chinese Chemical Letters, 2025, 36(12): 110908-. doi: 10.1016/j.cclet.2025.110908
19. [19]
  Huijuan Zhang , Chenglin Liang , Xinyi Ding , Meng Zhang , Siyu Lu , Lin Hou . Manganese-based nano-delivery system for sensitized anti-tumor immunotherapy via combined autophagy inhibition. Chinese Chemical Letters, 2025, 36(7): 110525-. doi: 10.1016/j.cclet.2024.110525
20. [20]
  Qi Wang , Yicong Gao , Feng Lu , Quli Fan . Preparation and Performance Characterization of the Second Near-Infrared Phototheranostic Probe: A New Design and Teaching Practice of Polymer Chemistry Comprehensive Experiment. University Chemistry, 2024, 39(11): 342-349. doi: 10.12461/PKU.DXHX202404141

Get Citation

PDF

XML

Metrics

PDF Downloads(22)
Abstract views(1314)
HTML views(69)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A2A adenosine receptors and histone deacetylases

Metrics

通讯作者: 陈斌, bchen63@163.com

Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A_2A adenosine receptors and histone deacetylases